WATER II (80-150 mL) procedural outcomes.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 26 4 2018
medline: 21 8 2019
entrez: 26 4 2018
Statut: ppublish

Résumé

To present early safety and feasibility data from a multicentre prospective study (WATER II) of aquablation in the treatment of symptomatic men with large-volume benign prostatic hyperplasia (BPH). Between September and December 2017, 101 men with moderate-to-severe BPH symptoms and prostate volume of 80-150 mL underwent aquablation in a prospective multicentre international clinical trial. Baseline demographics and standardized postoperative management variables were carefully recorded in a central independently monitored database. Surgeons answered analogue scale questionnaires on intra-operative technical factors and postoperative management. Adverse events up to 1 month were adjudicated by an independent clinical events committee. The mean (range) prostate volume was 107 (80-150) mL. The mean (range) operating time was 37 (15-97) min and aquablation resection time was 8 (3-15) min. Adequate adenoma resection was achieved with a single pass in 34 patients and with additional passes in 67 patients (mean 1.8 treatment passes), all in a single operating session. Haemostasis was achieved using either a Foley balloon catheter placed in the bladder under traction (n = 98, mean duration 18 h) or direct tamponade using a balloon inflated in the prostate fossa (n = 3, mean duration 15 h). No patient required electrocautery for haemostasis at the time of the primary procedure. The mean length of stay after the procedure was 1.6 days (range same day to 6 days). The Clavien-Dindo grade ≥2 event rate observed at 1 month was 29.7%. Bleeding complications were recorded in 10 patients (9.9%) during the index procedure hospitalization prior to discharge, and included six (5.9%) peri-operative transfusions. Aquablation is feasible and safe in treating men with men with large prostates (80-150 mL). The 6-month efficacy data are being accrued and will be presented in future publications (ClinicalTrials.gov number, NCT03123250).

Identifiants

pubmed: 29694702
doi: 10.1111/bju.14360
doi:

Substances chimiques

Water 059QF0KO0R

Banques de données

ClinicalTrials.gov
['NCT03123250']

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Pagination

106-112

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.

Auteurs

Mihir Desai (M)

Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Mo Bidair (M)

San Diego Clinical Trials, San Diego, CA, USA.

Naeem Bhojani (N)

University of Montreal Hospital Centre, University of Montréal, Montreal, QC, Canada.

Andrew Trainer (A)

Adult Paediatric Urology and Urogynecology, P.C., Omaha, NE, USA.

Andrew Arther (A)

Adult Paediatric Urology and Urogynecology, P.C., Omaha, NE, USA.

Eugene Kramolowsky (E)

Virginia Urology, Richmond, VA, USA.

Leo Doumanian (L)

Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Dean Elterman (D)

University Health Network University of Toronto, Toronto, ON, Canada.

Ronald P Kaufman (RP)

Albany Medical College, Albany, NY, USA.

James Lingeman (J)

Indiana University Health Physicians, Indianapolis, IN, USA.

Amy Krambeck (A)

Indiana University Health Physicians, Indianapolis, IN, USA.

Gregg Eure (G)

Urology of Virginia, Virginia Beach, VA, USA.

Gopal Badlani (G)

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Mark Plante (M)

University of Vermont Medical Centre, Burlington, VT, USA.

Edward Uchio (E)

VA Long Beach Healthcare System, Long Beach, CA, USA.

Greg Gin (G)

VA Long Beach Healthcare System, Long Beach, CA, USA.

Larry Goldenberg (L)

University of British Columbia, Vancouver, BC, Canada.

Ryan Paterson (R)

University of British Columbia, Vancouver, BC, Canada.

Alan So (A)

University of British Columbia, Vancouver, BC, Canada.

Mitch Humphreys (M)

Mayo Clinic Arizona, Scottsdale, AZ, USA.

Claus Roehrborn (C)

Department of Urology, UT Southwestern Medical Centre, University of Texas Southwestern, Dallas, TX, USA.

Steven Kaplan (S)

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Jay Motola (J)

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Kevin C Zorn (KC)

University of Montreal Hospital Centre, University of Montréal, Montreal, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH